Cargando…

Association of hypoglycaemia severity with clinical, patient‐reported and economic outcomes in US patients with type 2 diabetes using basal insulin

AIMS: To evaluate the clinical and patient‐reported outcomes and healthcare utilization and costs associated with patient‐reported hypoglycaemia in US adults with type 2 diabetes (T2D) treated with basal insulin. MATERIALS AND METHODS: This was an observational, cross‐sectional, survey‐based study o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meneghini, Luigi F., Lee, Lulu K., Gupta, Shaloo, Preblick, Ron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947635/ https://www.ncbi.nlm.nih.gov/pubmed/29316141 http://dx.doi.org/10.1111/dom.13208

Ejemplares similares

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
por: Mauricio, Dídac, et al.
Publicado: (2017)

Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
por: Zhou, Fang L., et al.
Publicado: (2019)

Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia
por: Reviriego, J, et al.
Publicado: (2008)

Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study
por: Gupta, Shaloo, et al.
Publicado: (2018)

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study
por: Bailey, Timothy S., et al.
Publicado: (2019)

Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
por: Frier, Brian M., et al.
Publicado: (2019)

Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems
por: Wang, Huiying, et al.
Publicado: (2022)

Insulin Hypoglycæmia
Publicado: (1948)

Approach to assessing the economic impact of insulin‐related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool
por: Parekh, W. A., et al.
Publicado: (2015)

Impact of delaying treatment intensification with a glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database
por: Tong, Liyue, et al.
Publicado: (2017)

Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
por: Heller, S. R., et al.
Publicado: (2015)

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
por: Blonde, Lawrence, et al.
Publicado: (2018)

Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes
por: Ali, Namam, et al.
Publicado: (2020)

A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
por: Kristensen, Peter Lommer, et al.
Publicado: (2012)

Clinical outcomes in real‐world patients with type 2 diabetes switching from first‐ to second‐generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study
por: Sullivan, Sean D., et al.
Publicado: (2018)

Early Insulin Treatment in Type 2 Diabetes: What are the pros?
por: Meneghini, Luigi F.
Publicado: (2009)

The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting
por: Meneghini, Luigi F., et al.
Publicado: (2019)

Hypoglycaemia in Type 2 diabetes
por: Amiel, S A, et al.
Publicado: (2008)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Reduced hypoglycaemia using liver‐targeted insulin in individuals with type 1 diabetes
por: Weinstock, Ruth S., et al.
Publicado: (2022)

Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review
por: Soares, Ana Rita, et al.
Publicado: (2023)

Comparable efficacy with similarly low risk of hypoglycaemia in patient‐ vs physician‐managed basal insulin initiation and titration in insulin‐naïve type 2 diabetic subjects: The Italian Titration Approach Study
por: Bonadonna, Riccardo C., et al.
Publicado: (2020)

Making surgical wards safer for patients with diabetes: reducing hypoglycaemia and insulin errors
por: Singh, Aminder, et al.
Publicado: (2018)

Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the US
por: Edelman, Steve, et al.
Publicado: (2020)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design
por: Agesen, Rikke Mette, et al.
Publicado: (2019)

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
por: Rosenstock, Julio, et al.
Publicado: (2016)

Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia
por: Hope, Suzy V., et al.
Publicado: (2018)

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

Concentrations of the Stress Hormone Copeptin Increase upon Hypoglycaemia in Patients with Type 1 Diabetes Dependent of Hypoglycaemia Awareness
por: Seelig, Eleonora, et al.
Publicado: (2013)

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
por: Pettus, Jeremy, et al.
Publicado: (2019)

Recurrent hypoglycaemia in type 2 diabetic patient due to hypothyroidism
por: Kumar, Alok
Publicado: (2015)

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100
por: Hollander, Priscilla A., et al.
Publicado: (2019)

Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies
por: Demirbilek, Huseyin, et al.
Publicado: (2023)

Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia
por: Goldenberg, Ronald M., et al.
Publicado: (2021)

Severe hypoglycaemia during intensive insulin therapy: a rare event in critically ill patients
por: Kaukonen, M, et al.
Publicado: (2007)

Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey
por: Reach, Gérard, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9blm8ijkbc2s2rftqohnh180cl